Walleye Capital’s BeOne Medicines Ltd ONC Stock Holding History

Walleye Capital’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29.7K	Hold	100	–	–	﹤0.01%	4010
2025 Q4	$30.4K	Buy	+100	New	+$32.7K	﹤0.01%	4189
2024 Q3	–	Sell	-2,700	Closed	-$385K	–	5988
2024 Q2	$385K	Buy	+2,700	New	+$416K	﹤0.01%	3733
2024 Q1	–	Sell	-1,100	Closed	-$198K	–	5997
2023 Q4	$198K	Buy	1,100 +500	+83%	+$90.5K	﹤0.01%	3681
2023 Q3	$108K	Sell	600 -2,700	-82%	-$534K	﹤0.01%	3909
2023 Q2	$588K	Buy	3,300 +2,300	+230%	+$530K	﹤0.01%	2307
2023 Q1	$216K	Buy	1,000 +200	+25%	+$48K	﹤0.01%	2415
2022 Q4	$176K	Buy	+800	New	+$147K	﹤0.01%	2122

Other funds holding ONC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Walleye Capital's ONC Position: Q1 2026 in Review

Walleye Capital increased its BeOne Medicines Ltd (ONC) stake by 616% in Q1 2026, buying an estimated $5.86M and bringing the position to 21,051 shares worth $6.25M. The position accounts for 0.03% of the portfolio, ranked #659.

Walleye Capital first reported a position in ONC in Q3 2023 and has held it in 9 quarters since. The position peaked at $19.8M in Q1 2025. 281 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

Walleye Capital held 21,051 shares of BeOne Medicines Ltd worth $6.25M as of Q1 2026.
Walleye Capital bought 18,109 BeOne Medicines Ltd shares in Q1 2026, an estimated $5.86M.
BeOne Medicines Ltd made up 0.03% of Walleye Capital's portfolio in Q1 2026, its #659 holding.
Walleye Capital first reported a position in BeOne Medicines Ltd in Q3 2023 and has held it in 9 quarters since.
Walleye Capital's BeOne Medicines Ltd position peaked at $19.8M in Q1 2025.
281 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.